New Content  edit
Get The App!

Loading the player...
FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy in Stage III Colon Cancer (ATOMIC)
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
Dr. Frank Sinicrope discusses FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy in Stage III Colon Cancer with DNA Mismatch repair of MSI (ATOMIC) at ASCO 2017. For the ability to view on your mobile phone please visit us at

This transcript is software driven, please understand there may be errors.  Should any inaccuracies or omissions be found, please notify for correction.

Hi. I'm Dr. Frank Sinicrope from the Mayo Clinic in Rochester, Minnesota, and I'm here to discuss my poster of a trial in progress. This is a phase III trial of adjuvant chemotherapy with FOLFOX, with or without atezolizumab, an anti-PD-L1 antibody that is being studied in stage III colon cancer patients with deficient DNA mismatch repair or microsatellite instability.

This is a randomized phase III trial where patients will be randomized to standard FOLFOX chemotherapy for six months or they will receive FOLFOX with atezolizumab for six months, with continuation of the atezolizumab for an additional six months. The study population is of course patients with resected stage III colon cancer that have deficient DNA mismatch repair determined by immunohistochemistry.

This will be a 700-patient trial to be done through the Alliance for Clinical Trials in Oncology. We're very excited about this trial because we think that it has the potential to be practice-changing, whereby we can use immunotherapy to hopefully improve the survival of treated patients. This study builds upon the data for immune checkpoint inhibition in metastatic colon cancer with microsatellite instability where high levels of response and extended survival have been seen. I appreciate the interest in the poster, and I thank you for your attention.